
Cantabio Pharmaceuticals receives grant from Michael J. Fox Foundation to develop a novel DJ-1 protein-based biomarker for Parkinson’s Disease
- co11ab
-
parkinson, biotech, drugdiscovery, cantabio, PD
- 17 August 2023
Grant enables the development of new detection technologies for DJ-1 in biofluids for potential early diagnosis of PD

Impact of patent positioning on successful investment rounds and acquisitions
- co11ab
-
IP, patents, microbiome, CGT, lifescience, biotech
- 11 August 2023
From patents to power moves: what are the key factors of creating strong and broad patents.

Advancing drug discovery to new heights with industry-leading technology platforms
- co11ab
-
biotech, drug, drugdiscovery
- 27 July 2023
Drug discovery can be a highly rewarding but it is also a high-risk business and resource-intensive.

Health innovation and development in Asia landscape
- co11ab
-
biotech, consumer, consumerhealth
- 12 July 2023
Perspectives on innovation and development, which bridges into successful commercialization of finished products.

The exploration of skin innovations and technologies
- co11ab
-
skin, dermatology, biotech, medtech
- 28 June 2023
Current trends in dermatological diseases and the potential areas of breakthroughs.

IP protection for healthcare start-ups
- co11ab
-
medtech, digital, IP
- 12 May 2023
Protecting intangible assets (IA), innovation and products beyond patents.

AIC forum to exchange best practices for innovation activities in the APAC MedTech space
- co11ab
-
innovation, APACMed, medtech
- 28 April 2023
Exchanging best practices for innovation activities in Asia Pacific Medtech space.

RNAscence Biotech and Nassim Plastic Surgery launched anti-scar product
- co11ab
-
biotech, medtech, antiscar, skincare, rnascence
- 27 April 2023
RNAscence Biotech and Nassim Plastic Surgery launched anti-scar product as part of their post-surgery recovery procedure.

Plasticell and LambdaGen join hands to exploit genome editing technologies
- co11ab
-
biotech, lambdagen, genetherapy
- 26 April 2023
Plasticell and LambdaGen to develop iPSC-derived CAR-NK allogeneic cancer immunotherapies.